<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206596</url>
  </required_header>
  <id_info>
    <org_study_id>307501</org_study_id>
    <secondary_id>91282</secondary_id>
    <secondary_id>Novel 2</secondary_id>
    <nct_id>NCT00206596</nct_id>
  </id_info>
  <brief_title>Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease</brief_title>
  <official_title>Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim (Leukine) Therapy in Patients With Cortico-Dependent Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Leukine to decrease the need
      for steroid treatment for Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE:
      This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer
      HealthCare, Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corticosteroid-free remission</measure>
    <time_frame>At the end of the study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroid-free remission or response to treatment as defined by the protocol</measure>
    <time_frame>At the end of the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using Inflammatory Bowel Disease Questionaire, SF 36 and EuroQol-derived visual scale (VAS)</measure>
    <time_frame>At the end of the study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim (Leukine)</intervention_name>
    <description>Once daily via subcutaneous injection for up 22 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>BAY86-5326</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily via subcutaneous injection for up 22 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  You must have active Crohn's disease at screening and been diagnosed with Crohn's
             disease within 6 months at screening.

          -  You must have steroid dependent disease (receiving between 10-40 mgs/day prednisone
             therapy for greater than 3 months prior to screening and had at least one unsuccessful
             attempt to reduce cortico-steroids due to worsening of disease).

          -  You must be able to give yourself an injection of study drug or have another person
             help you give the injection.

          -  You must not be pregnant and agree to use birth control if you are a sexually active
             male or female of childbearing potential.

        Exclusion Criteria:

          -  You may not be taking medications not allowed on this study.

          -  You may not have had GI surgery or bowel obstruction in the last 6 months.

          -  You may not have ever taken this drug or drugs of similar type in the past.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

